Achieving a better cure for cancer

More info

Introduction

CiMaas develops immunotherapy for cancer by optimally engaging the immune system.

Read more about CiMaas Immunotherapy products.

News /

CiMaas starts 2017 with successful first investment

MAASTRICHT, Mercurius Beleggingsmaatschappij B.V. and Werker Beleggingsmaatschappij B.V.  invest in CiMaas B.V. to realize cancer immunotherapy. CiMaas is now able to start a clinical trial in late 2017 for lung cancer patients with a cellular vaccine that will stimulate the patients’ own immune system to fight the disease.